Modality
Multispecific
MOA
HPK1i
Target
MALT1
Pathway
Checkpoint
Wet AMDHNSCCPNH
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
~May 2020
→ ~Aug 2021
Phase 2
Nov 2021
→ Mar 2029
Phase 2Current
NCT07165703
1,308 pts·PNH
2021-11→2026-03·Terminated
NCT05700724
324 pts·Wet AMD
2023-08→2029-03·Not yet recruiting
1,632 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-211w agoPh3 Readout· PNH
2029-03-122.9y awayPh3 Readout· Wet AMD
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2/3
Termina…
P2/3
Not yet…
Catalysts
Ph3 Readout
2026-03-21 · 1w ago
PNH
Ph3 Readout
2029-03-12 · 2.9y away
Wet AMD
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07165703 | Phase 2/3 | PNH | Terminated | 1308 | LiverFat |
| NCT05700724 | Phase 2/3 | Wet AMD | Not yet recr... | 324 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| ION-8812 | Ionis | Phase 1 | MALT1 |